Department of Health Policy & Behavioral Sciences, School of Public Health, Georgia State University, Atlanta, GA 30303, USA.
Laboratory Department, Metropolitan Hospital, Cape Coast P.O. Box 174, Ghana.
Int J Environ Res Public Health. 2022 May 28;19(11):6597. doi: 10.3390/ijerph19116597.
To date, about 37 million people are living with the human immunodeficiency virus (HIV) and an estimated 680,000 people have died from acquired immune deficiency syndrome (AIDS) related illnesses globally. While all countries have been impacted by HIV, some have been significantly more impacted than others, particularly countries in sub-Saharan Africa. The purpose of this paper was to identify progress made in HIV prevention globally, particularly in the areas of voluntary counseling and testing (VCT) uptake, access to antiretroviral therapy (ART), and HIV-related stigma. With the development of ART, a cocktail of medications for the treatment of HIV, VCT uptake increased, as it became apparent that the medication would only be prescribed after an HIV diagnosis through testing. Widely considered a critical gateway to HIV prevention and treatment, VCT is being implemented in many countries, and as a result, about 38 million people living with HIV in 2018 had access to ART. Regardless of this success, major challenges still remain. We did an electronic search of 135 articles in English related to global HIV progress and challenges indexed in PubMed, ResearchGate, Google, and other search engines from 1998 to 2021. Sixty articles met the inclusion criteria for this paper. Data on trends in ART coverage were obtained from the Joint United Nations Programme on HIV/AIDS (UNAIDS) website. These data were used to show ART coverage globally in World Health Organization (WHO) regions. It was found that while global successes have been chalked in the areas of VCT uptake and ART coverage, HIV-related stigma has impeded greater success. This paper summarizes and discusses global successes and challenges in HIV prevention efforts in the past four decades with a focus on VCT, ART, and HIV-related stigma.
截至目前,全球约有 3700 万人感染了人类免疫缺陷病毒(HIV),估计有 68 万人死于全球与获得性免疫缺陷综合征(AIDS)相关的疾病。虽然所有国家都受到 HIV 的影响,但有些国家受到的影响比其他国家更为严重,特别是撒哈拉以南非洲的国家。本文旨在确定全球在 HIV 预防方面取得的进展,特别是在自愿咨询和检测(VCT)参与度、获得抗逆转录病毒治疗(ART)以及与 HIV 相关的污名化方面。随着 ART 的发展,即治疗 HIV 的一组药物,VCT 的参与度增加了,因为显然只有通过检测诊断出 HIV 后才会开出这种药物。VCT 被广泛认为是 HIV 预防和治疗的关键门户,目前正在许多国家实施,因此,2018 年约有 3800 万 HIV 感染者可以获得 ART。尽管取得了这一成功,但仍存在重大挑战。我们在 PubMed、ResearchGate、Google 和其他搜索引擎中对 1998 年至 2021 年期间以英文发表的与全球 HIV 进展和挑战相关的 135 篇文章进行了电子检索。符合本文纳入标准的有 60 篇文章。ART 覆盖率趋势的数据来自联合国艾滋病规划署(UNAIDS)网站。这些数据用于显示世卫组织各区域的全球 ART 覆盖率。结果发现,尽管在 VCT 参与度和 ART 覆盖率方面取得了全球性的成功,但与 HIV 相关的污名仍然阻碍了更大的成功。本文总结和讨论了过去四十年中 HIV 预防工作在 VCT、ART 和与 HIV 相关的污名方面取得的全球成功和挑战。